Sleep Medicine Evaluation Note (Central Sleep Apnea/Hypoventilation)

Date/Time: [Date and time of encounter]

Location: [clinic / hospital inpatient consult]

Referring Clinician: [Name, specialty]

Primary Care Clinician: [Name]

Author/Credentials: [Name, credentials]

Data Sources: [Sources used: patient / family / caregiver / external records / prior sleep study reports / PAP or NIV device download / EHR / DME records]

Reason for Visit

[Referral question for high-acuity sleep-disordered breathing] (1–2 lines capturing the specific clinical concern: suspected central sleep apnea and/or sleep-related hypoventilation in the context of heart failure, opioid use, neurologic disease, stroke, high altitude, COPD overlap, or obesity hypoventilation. Include primary symptoms such as witnessed apneas, nocturnal dyspnea, morning headaches, hypoxemia, or excessive sleepiness. If consultative, state the consult question and expected outputs.)

History of Present Illness

[Opening summary sentence capturing acuity and key risk drivers]

[Symptom timeline and trajectory: onset, frequency, severity, progression; precipitating events such as new heart failure diagnosis, stroke/TIA, opioid dose changes, hospitalization, altitude exposure]

[Nocturnal symptoms: witnessed apneas, periodic breathing, gasping/choking, nocturnal dyspnea, awakenings, palpitations, snoring pattern]

[Daytime impact: sleepiness with Epworth Sleepiness Scale score if available, fatigue, morning headaches, cognitive changes]

[Prior therapies and responses: PAP/NIV trials with pressures/modes if known, adherence, benefits, side effects, treatment-emergent central events, reason for discontinuation]

[Central apnea phenotype screening: heart failure symptoms; arrhythmia history including atrial fibrillation; stroke/TIA or neurologic disease; renal failure; pulmonary hypertension; opioid exposure with agent, total daily dose, formulation, timing especially nighttime doses, duration, indication; co-sedatives including benzodiazepines, Z-drugs, gabapentinoids, muscle relaxants; alcohol use; high altitude residence or recent travel]

[Hypoventilation phenotype screening: symptoms of chronic hypercapnia such as morning headaches, hypersomnolence, confusion; orthopnea and positional tolerance; nocturnal hypoxemia history; home oxygen use with flow rate, timing, device; prior NIV use with settings and tolerance]

[Sleep schedule: usual bedtime, wake time, sleep quality; occupational driving or safety-sensitive duties if sleepiness present]

Prior Sleep Testing and Respiratory Support

• [Prior sleep study: type, date, AHI, central apnea index, obstructive index, oxygen nadir, time below 88%, CO2 metrics if available, Cheyne-Stokes pattern if present] (Repeat for additional studies.)
• [PAP/NIV therapy history: modality, pressures/modes, tolerance, residual AHI with central vs obstructive breakdown, emergence of central events on CPAP, reason for discontinuation]
• [Most recent device download: date range, average nightly usage, residual AHI with breakdown, leak data, interface type]
• [Records status] (If patient reports prior testing but report unavailable, document as patient-reported with plan to obtain.)

Comorbidities

• Cardiac: [Heart failure type, etiology, NYHA class; most recent LVEF with date and method; valvular disease; arrhythmias; ICD/CRT presence; recent cardiac hospitalizations] (If LVEF unknown, explicitly state unknown with plan to obtain.)
• Pulmonary: [COPD / asthma / ILD / bronchiectasis; baseline oxygen requirement; pulmonary hypertension; recent PFT values if available]
• Neuromuscular/Chest Wall: [Diagnosis; FVC percent predicted; MIP/MEP; bulbar symptoms; aspiration risk] (Include only when applicable.)
• Other Contributors: [CKD/ESRD with dialysis regimen; obesity with BMI; suspected OHS; relevant endocrine conditions]

Medications

• Medication reconciliation: [Active medication list with doses and schedules relevant to sleep-disordered breathing]
• Respiratory depressants: [Opioids with agent, total daily dose, formulation, timing, duration, indication, prescriber; benzodiazepines; Z-drugs; gabapentinoids; muscle relaxants; alcohol]
• Respiratory stimulants: [Acetazolamide or other agents if applicable]

Allergies

[Medication, latex, adhesive allergies with reactions] (Note relevance to PAP interfaces if applicable.)

Social History

• [Tobacco use status and pack-years]
• [Cannabis and alcohol use with timing relative to sleep]
• [Residence altitude and recent altitude travel]
• [Living situation affecting equipment use]
• [Occupation and safety-sensitive duties] (Include drowsy driving risks if sleepiness present.)

Review of Systems

[Focused cardiopulmonary and sleep-related ROS: dyspnea, orthopnea, edema, chest pain, palpitations, syncope, weakness, dysphagia, morning headaches, daytime somnolence] (Document pertinent positives and negatives actually discussed. Do not add "all others negative" unless explicitly performed.)

Physical Examination

• Vital signs: BP [value], HR [value], RR [value], SpO2 [value] [room air / supplemental O2 at flow rate], Weight [value], Height [value], BMI [value]
• General: [Appearance, work of breathing, mental status]
• Airway: [Nasal patency, oropharynx, neck circumference if obtained]
• Cardiovascular: [Rhythm/rate, murmurs, JVP, peripheral edema]
• Pulmonary: [Breath sounds, wheezes/crackles, accessory muscle use]
• Neuromuscular: [Strength pattern, bulbar signs, cough strength] (Include when relevant.)

Objective Data Reviewed

(Include only items reviewed today with sources and dates.)

• Sleep study: [Type, date, source, AHI, CAI/percent central, obstructive index, oxygen nadir, time below 88%, CO2 metrics if available, pattern description]
• PAP/NIV device download: [Date range, usage, residual AHI with breakdown, leak, mode/pressures, interface]
• Laboratory data: [ABG/VBG with date and oxygen condition during draw, serum bicarbonate, other relevant labs]
• Cardiac testing: [Echocardiogram with LVEF, date, method; BNP/NT-proBNP if available]
• Pulmonary testing: [PFTs, relevant imaging findings]

Assessment

(Rank-ordered problem list with highest acuity first. For each problem, document status as confirmed vs suspected, severity anchors, likely drivers, and safety considerations. Explicitly state when key information is unknown with plan to obtain. Do not infer LVEF, CO2 status, or coverage-qualifying results.)

1) Central Sleep Apnea

• Status: [confirmed by PSG / suspected based on device pattern / unclear]
• Subtype/drivers: [heart failure-related periodic breathing / opioid-associated / treatment-emergent / high altitude / neurologic / idiopathic]
• Severity anchors: [CAI, percent central events, symptom burden, oxygenation impact]
• Safety status: LVEF [known value / unknown with plan to obtain]; [presence/absence of concurrent hypoventilation]

2) Sleep-Related Hypoventilation

• Status: [confirmed / suspected / absent / unknown]
• Etiology: [OHS / neuromuscular weakness / COPD overlap / chest wall restriction / medication-related]
• Severity anchors: [PaCO2, serum bicarbonate, nocturnal saturation burden]
• Daytime hypercapnia: [present / absent / unknown with plan to determine]

3) Sleep-Related Hypoxemia

• Oxygen prescription: [flow, timing, device]
• Observed saturations: [nocturnal nadir, time below threshold]
• Risk statement: [Risk of oxygen without ventilatory support when hypercapnia risk present]

4) Relevant Comorbidities

[Cardiac, pulmonary, neuromuscular, and other conditions materially affecting management with current status]

Plan

Immediate Safety

[If red flags present: escalation plan for acute hypercapnic respiratory failure, severe hypoxemia, CO2 narcosis, or unstable cardiopulmonary status; disposition and urgent interventions] (Omit if not applicable.)

Diagnostic Testing

• [Sleep study type with rationale tied to cardiopulmonary disease, neuromuscular weakness, suspected hypoventilation, opioid use, or stroke history; CO2 monitoring specifications; oxygen protocol]
• [Conditional pathways if test selection depends on pending results like LVEF or ABG]
• [Additional diagnostics: ABG/VBG, serum bicarbonate, PFTs with MIP/MEP, echocardiogram, device download acquisition]

Therapy Pathway for Central Sleep Apnea

• Optimize contributors: [Heart failure optimization, opioid/sedative review, altitude mitigation, arrhythmia management]
• PAP/NIV strategy: [CPAP trial with reassessment criteria; escalation to BPAP S/T if indicated; ASV considerations]
• ASV candidacy: [LVEF status and rationale; shared decision-making documentation when LVEF borderline or unknown]
• Adjunct therapies: [Low-flow nocturnal oxygen with indication; acetazolamide with contraindications; positional strategies] (Include when appropriate.)
• Implantable therapy: [Phrenic nerve stimulation eligibility and sequencing] (Include when appropriate.)

Therapy Pathway for Hypoventilation

• Diagnostic confirmation: [ABG/VBG, serum bicarbonate, PFTs, PSG with TcCO2]
• Ventilatory support: [BPAP S/T or volume-assured NIV planning; initial settings or titration plan; interface strategy]
• Oxygen titration: [Target saturations; avoid hyperoxia if hypercapnia risk; reassessment plan]
• Adherence support: [Equipment education, DME coordination, follow-up schedule]

Oxygen/CO2 Management

• [Current oxygen prescription appropriateness with target saturations]
• [CO2 monitoring plan]
• [Safety counseling: fire risk, smoking cessation]

Care Coordination

• [Communication plan with relevant specialists]
• [Record requests pending]
• [DME coordination]

Follow-up

• [Timing: expedited vs routine with timeframe]
• [Objective metrics for reassessment: symptoms, ESS, device adherence, residual AHI, CO2/oxygenation data]

Orders

• [Sleep study: type, CO2 monitoring, oxygen protocol]
• [DME: device type/mode, settings or titrate in lab, interface, humidification]
• [Laboratory tests]
• [Imaging]
• [Referrals with clinical indication]

(Include only orders actually placed.)

Patient Education and Shared Decision-Making

• [Discussion of diagnosis, uncertainties, and rationale for testing]
• [PAP/NIV options with benefits/risks]
• [ASV or implantable device counseling if applicable: risks, alternatives, LVEF-based eligibility, expected benefit targets]
• [Oxygen therapy counseling if applicable: benefits, hypercapnia risks, fire safety]
• [Drowsy driving and work safety counseling if sleepiness or hypoventilation-related somnolence present]

Billing Support

[Time-based statement: total time spent on this date] or [MDM-based summary highlighting problems addressed, data reviewed, and risk] (Optional; include if needed for billing documentation.)

Signature

[Electronic signature, credentials, date/time]

(Meta-instructions: When clinically important information is unknown—especially LVEF, hypercapnia status, or prior study results—explicitly document as unknown with a concrete plan to obtain rather than omitting. Do not infer LVEF values, CO2 status, or coverage-qualifying results. For therapy recommendations in heart failure patients, always document LVEF status and rationale for ASV candidacy. Omit sections that do not apply to the encounter rather than leaving empty placeholders.)